Saniona to transfer its listing to Nasdaq First North Premier as a step towards Nasdaq Stockholm
Saniona, a leading biotech company in the field of ion channels, today announces that it has submitted an application for trading on Nasdaq First North Premier as a step in company’s plans to list its shares on Nasdaq Stockholm Small Cap. If Saniona’s shares are admitted for trading on Nasdaq First North Premier, the Company will delist its shares from AktieTorget. The list transfer to Nasdaq First North Premier is planned to take place in May 2016 and Saniona has initiated the preparations to list its shares on Nasdaq Stockholm Small Cap later this year.
All Saniona’s shares will automatically be transferred for trading at Nasdaq First North Premier. The individual shareholders do not need to do anything. Saniona’s shares can be traded normally at AktieTorget until the first trading day on Nasdaq First North Premier.
“We have been very pleased about the listing at AktieTorget. The listing on AktieTorget in April 2014 gave us the possibilities to expand our research and development in a tremendous way. We have in short time gone from an early stage research based company to a biotech drug development company with a pipeline of products of which one program has entered a Phase 2 clinical trial last month. We are aiming at listing the company’s shares on Nasdaq Stockholm Small Cap later this year and see Nasdaq First North Premier as a natural next step in professionalizing the company further together with our present and future shareholders,” says Jørgen Drejer, CEO of Saniona.
For more information, please contact
Thomas Feldthus, EVP and CFO, Saniona, Mobile: +45 2210 9957, E-mail: email@example.com
Saniona is a research and development company focused on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases and treatment of pain. The company has a significant portfolio of potential drug candidates at pre-clinical and clinical stage. The research is focused on ion channels, which makes up a unique protein class that enables and controls the passage of charged ions across cell membranes. Saniona has ongoing collaboration agreements with Upsher-Smith Laboratories, Inc., Productos Medix, S.A de S.V and Saniona’s Boston based spinout Ataxion Inc., which is financed by Atlas Venture Inc. and Biogen Inc. Saniona is based in Copenhagen, Denmark, where it has a research center of high international standard. Saniona is listed at AktieTorget since April 2014 and has about 3,000 shareholders. The company’s share is traded under the ticker SANION. Read more at www.saniona.com.